Expert Interview: Frequently Asked Questions (FAQs) for First Line (1L) Treatment Decision making ACE OncoCast

Platinum-based chemotherapy (CT) has been the preferred treatment for patients with unresectable locally advanced and/or metastatic (LA/m) urothelial cancer (UC) for several decades. With the evolving development of immunotherapy in the first-line (1L) setting, the standard management approach for LA/m UC consisted of cisplatin-based CT in cisplatin eligible patients or carboplatin-based CT in cisplatin ineligible patients followed by maintenance avelumab (an anti-PD-L1 inhibitor) in those wh...